 BURLINGAME, Calif.--BUSINESS WIRE--Humanigen, Inc. NASDAQ: HGEN Humanigen, a clinical stage biopharmaceutical company developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases, today announced completing enrollment in its Phase 1 bioimaging study of ifabotuzumab in patients with recurrent glioblastoma multiforme GBM. Ifabotuzumab, or ifab, is the Companys proprietary anti-EphA3 monoclonal antibody. This trial is supported by 